A method of treating Atrial Fibrillation or a pre-Atrial Fibrillation condition in a mammal, preferably a human, comprising administering a therapeutically effective amount of one of organic or inorganic sulfide, organic or inorganic nitrite, both organic or inorganic sulfide and organic or inorganic nitrite, or pharmacologically acceptable salts, solvates, esters, amides, clathrates, stereoisomers, enantiomers, prodrugs or analogs thereof, or a combination thereof.

The present application relates to a system for removal of nitrate from water. The system includes a first reactor comprising a porous oxide-derived silver electrode (OD-Ag) for electrocatalytic reduction of nitrate (NO.sub.3.sup.?) to nitrite (NO.sub.2.sup.?) and a second reactor comprising a Pd-based catalyst for catalytic reduction of nitrite (NO.sub.2.sup.?). Also disclosed is a method of removing nitrate from water.

The present application relates to a system for removal of nitrate from water. The system includes a first reactor comprising a porous oxide-derived silver electrode (OD-Ag) for electrocatalytic reduction of nitrate (NO.sub.3.sup.?) to nitrite (NO.sub.2.sup.?) and a second reactor comprising a Pd-based catalyst for catalytic reduction of nitrite (NO.sub.2.sup.?). Also disclosed is a method of removing nitrate from water.

A present disclosure describes about an improved form of purified crystalline sodium nitrite. The said form of sodium nitrite may comprise a purity level between 99% to 99.2%. The form of sodium nitrite may also comprise an amount of sodium nitrate no greater than 0.7%. The present disclosure also relates to a method of obtaining an improved form of purified crystalline sodium nitrite with minimum impurities.

A present disclosure describes about an improved form of purified crystalline sodium nitrite. The said form of sodium nitrite may comprise a purity level between 99% to 99.2%. The form of sodium nitrite may also comprise an amount of sodium nitrate no greater than 0.7%. The present disclosure also relates to a method of obtaining an improved form of purified crystalline sodium nitrite with minimum impurities.

Disclosed are compositions that comprise an organic electrochemical mediator and a gasotransmitter salt which converts into a gasotransmitter via electron transfer. Also disclosed are bandages and wound dressings comprising the subject gasotransmitters, and methods of making a gasotransmitters, comprising exposing the compositions to a voltage sufficient to reduce the water soluble organic mediator. Further disclosed are methods of treating a variety of trauma and disease states by applying a therapeutically effective amount of at least one gasotransmitter thereto, and methods of generating an effective dose of the gasotransmitter generated from electrolytic reaction involving the gasotransmitter-generating compositions.

Disclosed are compositions that comprise an organic electrochemical mediator and a gasotransmitter salt which converts into a gasotransmitter via electron transfer. Also disclosed are bandages and wound dressings comprising the subject gasotransmitters, and methods of making a gasotransmitters, comprising exposing the compositions to a voltage sufficient to reduce the water soluble organic mediator. Further disclosed are methods of treating a variety of trauma and disease states by applying a therapeutically effective amount of at least one gasotransmitter thereto, and methods of generating an effective dose of the gasotransmitter generated from electrolytic reaction involving the gasotransmitter-generating compositions.

Provided herein is a process for preparing a nitrate comprising contacting a nitrogen oxide with a metal oxide under milling conditions to form a nitrate.

Provided herein is a process for preparing a nitrate comprising contacting a nitrogen oxide with a metal oxide under milling conditions to form a nitrate.

Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.